

**Fellow Publications/Presentations
January through December 2018**

Publications

1. **Chakraborty R**, Sidana S, Shah GL, et. al. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. *Biol Blood Marrow Transplant.* 2018 Nov 28. pii: S1083-8791(18)30758-4. PMID: 30500439
2. **Chakraborty R**, Muchtar E, Kumar SK, et. al. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. PMID: 29707759
3. **Chakraborty R**, Hamilton BK, Hashmi SK, et. al. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant.* 2018 Aug;24(8):1546-1553. PMID: 29626515
4. **Chakraborty R**, Gertz MA. Will we be able to afford a cure in multiple myeloma? *Leuk Lymphoma.* 2018 Jan;59(1):1-2. PMID: 28629244
5. **Khouri J**, Kin A, Thapa B, Reu FJ, et. al. Daratumumab proves safe and highly effective in AL amyloidosis. *Br J Haematol.* 2018 Jun 25. doi: 10.1111/bjh.15455. PMID: 29938774
6. **Khouri J**, Rybicki L, Majhail N. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. *J Clin Apher.* 2018 Jun;33(3):303-309. PMID: 29134688
7. **Koshkin V**, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. *Ther Adv Urol.* 2018 Nov 11;10(12):445-454. PMID: 30574205
8. **Koshkin VS**, Garcia JA, Reynolds J, et. al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. *Clin Cancer Res.* 2019 Jan 1;25(1):210-221. PMID: 30172552
9. **Koshkin VS**, Grivas P. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. *Clin Genitourin Cancer.* 2018 Oct;16(5):413-419. PMID: 30172552
10. **Koshkin VS**, Grivas P. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. *Transl Androl Urol.* 2018 Jun;7(3):504-507. PMID: 30050808
11. Gopalakrishnan D, **Koshkin VS**, Ornstein MC, et. al. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. PMID: 29892196
12. **Koshkin VS**, Grivas P. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. *Curr Oncol Rep.* 2018 Apr 11;20(6):48. PMID: 29644490

13. Barata PC, Gopalakrishnan D, **Koshkin VS**, et. al. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. *Target Oncol*. 2018 Jun;13(3):353-361. PMID: 29623487
14. **Koshkin VS**, Barata PC, Rybicki LA, et. al. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. *Clin Genitourin Cancer*. 2018 Aug;16(4):e879-e892. PMID: 29576445
15. **Koshkin VS**, Barata PC, Zhang T, et. al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. *J Immunother Cancer*. 2018 Jan 29;6(1):9. PMID: 29378660
16. Thota S, **Patel BJ**, **Sadaps M**, et. al. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. *Br J Haematol*. 2018 Oct;183(1):133-136. PMID: 28905372
17. **Patel SS**, Rybicki LA, Corrigan D, et. al. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Oct 30. PMID: 30375493
18. **Patel SS**, Majhail NS. Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities. *Curr Hematol Malig Rep*. 2018 Dec;13(6):576-580. PMID: 30324550
19. **Patel SS**, Majhail NS. Twitter Use in the Hematopoietic Cell Transplantation Community. *Curr Hematol Malig Rep*. 2018 Feb;13(1):53-58. PMID: 9374370
20. **Patel SS**, Rybicki LA, Corrigan D, et. al. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 May;24(5):1029-1034. PMID: 29369800
21. Khunger M, **Patil PD**, Khunger A, et. al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. *PLoS One*. 2018 Oct 25;13(10):e0197743. PMID: 30359383
22. **Patil PD**, Fernandez AP, Velcheti V, et. al. Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. *Oncologist*. 2019 Jan;24(1):4-8. PMID: 30355774
23. **Patil PD**, Sultan S, Hahn MF, et. al. Incidental extensive adenocarcinoma in lungs explanted from a transplant recipient with an idiopathic pulmonary fibrosis flare-up: A clinical dilemma. *Respir Med Case Rep*. 2018 Jun 12;25:45-48. PMID: 29942737
24. Omar A, **Patil PD**, Hoshi S, et. al. A 68-Year-Old Lung Transplant Recipient With Shortness of Breath, Weight Loss, and Abnormal Chest CT. *Chest*. 2018 Jun;153(6):e153-e157. PMID: 29884278
25. Ross MD, Biswas Roy S, **Patil PD**, et. al. Coexistent Non-Small Cell Carcinoma and Small Cell Carcinoma in a Patient Presenting with Hyponatremia. *Case Rep Pulmonol*. 2018 Feb 20;2018:1718326. PMID: 29675281

26. Biswas Roy S, Ross MD, **Patil PD**, et. al. Primary *Nocardia* Infection Causing a Fluorodeoxyglucose-Avid Right Renal Mass in a Redo Lung Transplant Recipient. Case Rep Transplant. 2018 Feb 7;2018:9752860. PMID: 29568659
27. **Patil PD**, Burotto M, Velcheti V. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Expert Rev Mol Diagn. 2018 Mar;18(3):297-305. PMID: 29430978
28. Chaddha U, **Patil PD**, Omar A, et. al. A 47-Year-Old Man With Fever, Dry Cough, and a Lung Mass After Redo Lung Transplantation. Chest. 2018 Jun;153(6):e147-e152. PMID: 29884277
29. **Sawalha Y**, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol. 2018 Apr 10;7(1):IJH02. PMID: 30302234
30. **Sawalha Y**, Hill BT, Rybicki LA. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e95-e102. PMID: 29208403
31. Hill BT, Nastoupil L, **Winter AM**. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2018 Dec 21. PMID: 30575016
32. **Winter A**, Rybicki L, Shah SN, et. al. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2018 May;59(5):1195-1201. PMID: 28853617
33. **Zahoor H**, Grivas P. The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer. Eur Urol. 2018 Dec 14. pii: S0302-2838(18)30964-3. PMID: 30558899
34. **Zahoor H**, Barata PC, Jia X. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018 Oct 17;6(1):107. PMID: 30333065
35. **Zahoor H**, Pavicic PG Jr, Przybycin C, et. al. Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. Medicine (Baltimore). 2018 Sep;97(37):e12344. PMID: 30212988
36. **Zahoor H**, Rini BI, Ornstein MC. Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more. Oncotarget. 2017 Dec 6;9(18):14036-14037. PMID: 29581822
37. **Zahoor H**, Elson P, Stephenson A, et. al. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. PMID: 29154041

Poster Presentations/Abstracts

1. **Chakraborty R**, et. al. Impact of Clinical versus Biomedical Progression on Post-Progression Survival in Multiple Myeloma. ASH Annual Meeting. December 2019 (Poster)
2. **Hu R**, Differences in Genomic Patterns Between African Americans and Whites with Acute Myeloid Leukemia. ASH Annual Meeting. San Diego, CA. December 2018 (Poster).
3. **Khouri J**, Reu F, Majhail NS, et. al. Low-Dose Lenalidomide after Non-Myeloablative Allogeneic Hematopoietic Cell Transplant with Bortezomib as GVHD Prophylaxis in High-Risk Multiple Myeloma. BMT Tandem Meeting. Salt Lake City, UT. February 2018 (Poster)
4. **Kishtagari, A**. A First-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis. ASH Annual Meeting. San Diego, CA. December 2018. (**Oral**)
5. **Koshkin V**, Prognostic Value of CD56, ASCL1 and Other Biomarkers in Small Cell Bladder Cancer (SCBC). ASCO Genitourinary Cancer Symposium. San Francisco, CA. February 2018. (Poster)
6. **Koshkin V**, Barata PC, Zahoor H, et. al. Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function. ASCO Genitourinary Cancer Symposium. San Francisco, CA. February 2018. (Poster)
7. **Kunapareddy**. Implementation of Individualized Care Plans in High Risk Oncology Patients: A Team Based Method to Decrease Unnecessary Utilization. ASCO Annual Meeting. June 2018. (Poster)
8. **Madanat, Y**, Sekeres M, Mukherjee S, et. al. Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS). Society of Hematologic Oncology (SOHO) Annual Meeting. September 2018. (**Oral**)
9. **Madanat, Y**, Sekeres M., Mukherjee S, et. al. Genomic Biomarkers Predict Responses / Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndrome. ASH Annual Meeting. San Diego, CA. December 2018. (Poster)
10. **Lee, S**. Cost and Value Analysis of Standard Versus Rapid Daratumumab Infusion in Multiple Myeloma. ASH Annual Meeting. San Diego, CA. December 2018 (Poster).
11. **Lee, S**. Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis. ASH Annual Meeting. San Diego, CA. December 2018 (Poster)
12. **Patel, B**. Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia. ASH Annual Meeting. San Diego, CA. December 2018. (Poster)
13. **Patel, B**. Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia. ASH Annual Meeting. San Diego, CA. December 2018 (Poster)
14. **Patel S**, Rybicki L, Corrigan D, et. al. Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant Recipients. BMT Tandem Meeting. Salt Lake City, UT. February 2018. (Poster)

15. **Patel S**, Rybicki L, Yurch M, et. al. Impact of MHC Class I Chain-Related Gene A (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation Outcomes. BMT Tandem Meeting. Salt Lake City, UT. February 2018 (Poster)
16. **Patel S**, Rybicki L, Yurch M, et. al. Impact of MHC Class I Chain-Related Gene A (MICA) Dimorphisms on Outcomes after Umbilical Cord Blood Transplantation (UCBT). BMT Tandem Meeting. Salt Lake City, UT. February 2018 (Poster)
17. **Patel S.**, Rybicki L, Yurch M, Thomas D, et. al. Impact of MHC Class I Chain-Related Gene A (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplant Outcomes. Acute Leukemia Forum. Newport Beach, CA. April 2018 (Poster)
18. **Patel S.**, Rybicki L, Yurch M, Thomas D, et. al. Impact of MHC Class I Chain-Related Gene A (MICA) Dimorphisms on Outcomes after Umbilical Cord Blood Transplant. Acute Leukemia Forum. Newport Beach, CA. April 2018 (Poster)
19. **Patil P**, Bera K, Vaidya P, et. al. Pre-treatment Radiomic Features Can Differentiate Hyperprogression from Other Response Patterns Following Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. IASLC World Conference on Lung Cancer. Toronto, Canada. September 2018 (Poster)
20. **Sadaps M**, Funchain P, Heald B, Huether R, et.al. A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer. San Francisco, CA. January 2019 (Poster).
21. **Sawalha Y**, McMichael, Rybicki L, Sussman T. Risk of Post-Transplant Lymphoproliferative Disorders (PTLD) in Solid Organ Transplantation Patients with EBV Viremia. ASH Annual Meeting. San Diego, CA. (Poster)
22. **Winter A**, Nastoupil L, Becnel M, et. al. Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade Early Progression on Overall Survival. ASH Annual Meeting. December 2018. San Diego, CA. (Poster)
23. **Zahoor H**, et. al. Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. ASCO Genitourinary Cancer Symposium. February 2018. San Francisco, California. (Poster)